Clinical Trials

Inclusion Criteria

• Age ≥ 18 years.
• Histologically confirmed malignancy.
• Primary, recurrent, or metastatic skin or superficial soft tissue tumor amenable to palliative orthovoltage radiotherapy.
• Anticipated life expectancy ≥ 30 days and anticipated capacity for follow up for ≥ 30 days.
• Negative pregnancy test done ≤ 28 days prior to registration, for biological women of childbearing potential only.
• Willing to provide written informed consent.
• Willing to allow baseline and follow up photograph acquisition for response and toxicity assessment.
• Willing and able to return to enrolling institution for follow-up during the Active Monitoring Phase of the study.
• Willing to provide blood and tissue samples for correlative research purposes (see Section 6.2).

Exclusion Criteria

• Hematologic, germ cell, or any other tumor that the investigational team would deem to have a high likelihood of clinical complete response with standard palliative radiotherapy (8 Gy in 1, 30 Gy in 10, etc.).
• Prior radiotherapy targeting the lesion presenting for treatment or prior adjacent radiotherapy if > 10 Gy overlaps with a portion of the planned target.
• Treatment with a BRAF inhibitor, monoclonal antibodies targeting VEGF (bevacizumab or ramucirumab) or small molecule inhibitors inhibiting VEGF within the last 2 weeks or planned treatment with BRAF inhibitor within 4 weeks after radiation.
• Planned treatment with cytotoxic chemotherapy within the 4 weeks after MBRT (the DLT period).
• Treatment with an investigational drug therapy within 2 weeks prior to or 4 weeks (the DLT monitoring period) after MBRT
• Any tumor with direct extension into the spine such that targeting the spine/spinal cord could not be avoided.